All updated as on -
In 2023, the market for nasal vaccines was estimated to be worth US$ 416.80 million; by 2030, it is anticipated to have grown to US$ 742.19 million, with a compound annual growth rate (CAGR) of 9.6%.
The COVID 19 Nasal Vaccine is designed for primary immunization against COVID-19 in the 18+ age group and is only to be used in emergency cases. For children and adults with trypanophobia, or a fear of needles, nasal vaccines are a better choice than conventional jabs. A COVID 19 nasal vaccine is given either orally or nasally. It is believed that it will affect the mucosal lining and start an immune response where the virus enters the human body. It most likely blocks the virus at the point of entrance, so preventing further propagation. This is referred to as "sterilising immunity" by experts. When this immunization is given nasally, the body reacts severely, especially the nose and respiratory system.
The pharmaceutical industry's sector that focuses on the development, manufacturing, and distribution of vaccinations given via the nasal route is known as the "nasal vaccines market." Nasal vaccinations are a type of immunization that are administered intravenously, generally as a nasal spray. These vaccines are made to elicit an immune response in the mucosal surfaces of the respiratory tract, offering defense against diseases of the respiratory system brought on by particular pathogens, including influenza, COVID-19, and others.
The market for nasal vaccines has grown significantly in recent years due to factors like the rising demand for needle-free vaccine delivery methods, the potential for improved mucosal immunity, ease of administration, and the potential for increased patient compliance, especially in the pediatric population. For a variety of viral disorders, nasal vaccinations are being created, and current research intends to broaden their applicability.
The need to produce goods that can lessen the load on hospitals and clinics as well as the growing urgency to limit the rapid spread of the COVID-19 virus are what are causing the market to rise. The introduction of this viral-relieving medicine will lessen the virus load in the environment because it has been observed that clinics and hospitals are the primary locations where the virus is transmitted. The introduction and widespread use of the national covid-19 vaccine will assist those nations with a significant number of covid-19 cases in restructuring their healthcare systems and reducing the spread of the disease. In addition to this, the company asserts that the goods have been proven in scientific trials to be secure, dependable, and efficient for use on people.
Due to accelerated R&D efforts, active government collaborations, and the presence of major pharmaceutical companies in the region, the Asia Pacific nasal vaccines market is anticipated to have comparatively significant revenue growth during the forecast period. Pharmaceutical companies in the area are concentrating on creating COVID-19 vaccines and medicines to treat other respiratory illnesses.
China and India are focusing on COVID-19 vaccines that come in nasal spray form. High market revenue growth in North America can be attributed to the country's market and the region's growing emphasis on medical research. Due to an increase in clinical research activities in the region, revenues from the Latin American nasal vaccines market are growing. Due to the region's subpar medical and scientific infrastructure, the market for nasal vaccinations in the Middle East and Africa remains stagnating. However, improvements in Israeli and South African medical technology would result in a beneficial development.
Report Coverage
Global Nasal Vaccines research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Nasal Vaccines report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Nasal Vaccines competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Nasal Vaccines market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Nasal Vaccines market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Nasal Vaccines market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Amcyte Pharma, SaNOtize, Beijing Wantai Biological Pharmacy Enterprise, Marinomad Biotech, Ena Respiratory, AuraVax Therapeutics Inc., Meissa Vaccines, AstraZeneca, GlaxoSmithKline plc, Pfizer Inc., Serum Institute of India Pvt. Ltd., Sanofi Pasteur SA, Johnson & Johnson Services, Inc., Sinovac Biotech Ltd., Bharat Biotech International Limited, Altimmune, Inc., BiondVax Pharmaceuticals Ltd., FluGen Inc., Vaxart, Inc., Intravacc, Ennaid Therapeutics, LLC, Gamma Vaccines Pty Ltd.
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Nasal Vaccines market based on the below-mentioned segments:
Global Nasal Vaccines Market, By Offering
Vaccine
Off-Load
Others
Global Nasal Vaccines Market, By End User
Hospital
Clinics
Home Care Settings
Others
Global Nasal Vaccines market, Regional Analysis
The COVID 19 Nasal Vaccine is designed for primary immunization against COVID-19 in the 18+ age group and is only to be used in emergency cases. For children and adults with trypanophobia, or a fear of needles, nasal vaccines are a better choice than conventional jabs. A COVID 19 nasal vaccine is given either orally or nasally. It is believed that it will affect the mucosal lining and start an immune response where the virus enters the human body. It most likely blocks the virus at the point of entrance, so preventing further propagation. This is referred to as "sterilising immunity" by experts. When this immunization is given nasally, the body reacts severely, especially the nose and respiratory system.
The pharmaceutical industry's sector that focuses on the development, manufacturing, and distribution of vaccinations given via the nasal route is known as the "nasal vaccines market." Nasal vaccinations are a type of immunization that are administered intravenously, generally as a nasal spray. These vaccines are made to elicit an immune response in the mucosal surfaces of the respiratory tract, offering defense against diseases of the respiratory system brought on by particular pathogens, including influenza, COVID-19, and others.
The market for nasal vaccines has grown significantly in recent years due to factors like the rising demand for needle-free vaccine delivery methods, the potential for improved mucosal immunity, ease of administration, and the potential for increased patient compliance, especially in the pediatric population. For a variety of viral disorders, nasal vaccinations are being created, and current research intends to broaden their applicability.
The need to produce goods that can lessen the load on hospitals and clinics as well as the growing urgency to limit the rapid spread of the COVID-19 virus are what are causing the market to rise. The introduction of this viral-relieving medicine will lessen the virus load in the environment because it has been observed that clinics and hospitals are the primary locations where the virus is transmitted. The introduction and widespread use of the national covid-19 vaccine will assist those nations with a significant number of covid-19 cases in restructuring their healthcare systems and reducing the spread of the disease. In addition to this, the company asserts that the goods have been proven in scientific trials to be secure, dependable, and efficient for use on people.
Due to accelerated R&D efforts, active government collaborations, and the presence of major pharmaceutical companies in the region, the Asia Pacific nasal vaccines market is anticipated to have comparatively significant revenue growth during the forecast period. Pharmaceutical companies in the area are concentrating on creating COVID-19 vaccines and medicines to treat other respiratory illnesses.
China and India are focusing on COVID-19 vaccines that come in nasal spray form. High market revenue growth in North America can be attributed to the country's market and the region's growing emphasis on medical research. Due to an increase in clinical research activities in the region, revenues from the Latin American nasal vaccines market are growing. Due to the region's subpar medical and scientific infrastructure, the market for nasal vaccinations in the Middle East and Africa remains stagnating. However, improvements in Israeli and South African medical technology would result in a beneficial development.
Report Coverage
Global Nasal Vaccines research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Nasal Vaccines report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Nasal Vaccines competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Nasal Vaccines market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Amcyte Pharma, SaNOtize, Beijing Wantai Biological Pharmacy Enterprise, Marinomad Biotech, Ena Respiratory, AuraVax Therapeutics Inc., Meissa Vaccines, AstraZeneca, GlaxoSmithKline plc, Pfizer Inc., Serum Institute of India Pvt. Ltd., Sanofi Pasteur SA, Johnson & Johnson Services, Inc., Sinovac Biotech Ltd., Bharat Biotech International Limited, Altimmune, Inc., BiondVax Pharmaceuticals Ltd., FluGen Inc., Vaxart, Inc., Intravacc, Ennaid Therapeutics, LLC, Gamma Vaccines Pty Ltd. |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Nasal Vaccines Market from 2021 to 2030.
- Market Forecast for Nasal Vaccines Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Nasal Vaccines competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Nasal Vaccines
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Nasal Vaccines market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Nasal Vaccines market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Amcyte Pharma, SaNOtize, Beijing Wantai Biological Pharmacy Enterprise, Marinomad Biotech, Ena Respiratory, AuraVax Therapeutics Inc., Meissa Vaccines, AstraZeneca, GlaxoSmithKline plc, Pfizer Inc., Serum Institute of India Pvt. Ltd., Sanofi Pasteur SA, Johnson & Johnson Services, Inc., Sinovac Biotech Ltd., Bharat Biotech International Limited, Altimmune, Inc., BiondVax Pharmaceuticals Ltd., FluGen Inc., Vaxart, Inc., Intravacc, Ennaid Therapeutics, LLC, Gamma Vaccines Pty Ltd.
Primary Target Market
- Market Players of Nasal Vaccines
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Nasal Vaccines market based on the below-mentioned segments:
Global Nasal Vaccines Market, By Offering
Vaccine
Off-Load
Others
Global Nasal Vaccines Market, By End User
Hospital
Clinics
Home Care Settings
Others
Global Nasal Vaccines market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive nasal vaccines market market research and competitor analysis for your business to help you develop more profound insights into the nasal vaccines market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the nasal vaccines market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.